Skip to main content

. 1968 Sep;22(3):415–421. doi: 10.1038/bjc.1968.49

Clinical trial of protamine in the treatment of malignant diseases.

PMCID: PMC2008396 PMID: 4878637

415

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

MUGGLETON P. W., MACLAREN J. G., DYKE W. J. EFFECT OF PROTAMINE SULPHATE ON EXPERIMENTAL TUMOURS IN MICE. Lancet. 1964 Feb 22;1(7330):409–410. doi: 10.1016/s0140-6736(64)92788-6. [DOI] [PubMed] [Google Scholar]
O'MEARA R. A., O'HALLORAN M. J. PROTAMINE DERIVATIVES IN TREATMENT OF ADVANCED CARCINOMA OF THE BREAST. Lancet. 1963 Sep 21;2(7308):613–614. doi: 10.1016/s0140-6736(63)90400-8. [DOI] [PubMed] [Google Scholar]
O'MEARA R. A., THORNES R. D. Some properties of the cancer coagulative factor. Ir J Med Sci. 1961 Mar;423:106–112. doi: 10.1007/BF02952952. [DOI] [PubMed] [Google Scholar]
THORNES R. D., MARTIN W. T. The cytopathic effect of fibrinolytic agents and human placental fractions on HeLa cells. Ir J Med Sci. 1961 Nov;431:487–494. doi: 10.1007/BF02953743. [DOI] [PubMed] [Google Scholar]
THORNES R. D., O'MEARA R. A. A method of detecting and estimating inhibitors of the cancer coagulative factor. Ir J Med Sci. 1961 Aug;428:361–365. doi: 10.1007/BF02953365. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES